These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 37515588

  • 41. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG, Shukla AP, Aronne LJ.
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [Abstract] [Full Text] [Related]

  • 42. Glucagon is a primary controller of hepatic glycogenolysis and gluconeogenesis during muscular work.
    Wasserman DH, Spalding JA, Lacy DB, Colburn CA, Goldstein RE, Cherrington AD.
    Am J Physiol; 1989 Jul; 257(1 Pt 1):E108-17. PubMed ID: 2665514
    [Abstract] [Full Text] [Related]

  • 43. Physiological responses to leptin levels in lipodystrophy: a model for other hypoleptinemias?
    Rosenbaum M, Leibel RL.
    J Clin Invest; 2018 Aug 01; 128(8):3237-3239. PubMed ID: 30010621
    [Abstract] [Full Text] [Related]

  • 44. Metreleptin: first global approval.
    Chou K, Perry CM.
    Drugs; 2013 Jun 01; 73(9):989-97. PubMed ID: 23740412
    [Abstract] [Full Text] [Related]

  • 45. Recurrent hypoglycemia increases hepatic gluconeogenesis without affecting glycogen metabolism or systemic lipolysis in rat.
    Liu Z, Zhang L, Qian C, Zhou Y, Yu Q, Yuan J, Lv Y, Zhang L, Chang X, Li Y, Liu Y.
    Metabolism; 2022 Nov 01; 136():155310. PubMed ID: 36063868
    [Abstract] [Full Text] [Related]

  • 46. Gluconeogenesis and hepatic glycogenolysis during exercise at the lactate threshold.
    Emhoff CA, Messonnier LA, Horning MA, Fattor JA, Carlson TJ, Brooks GA.
    J Appl Physiol (1985); 2013 Feb 01; 114(3):297-306. PubMed ID: 23239870
    [Abstract] [Full Text] [Related]

  • 47. Gluconeogenesis is reduced from alanine, lactate and pyruvate, but maintained from glycerol, in liver perfusion of rats with early and late sepsis.
    de Souza Galia WB, Biazi GR, Frasson-Uemura IG, Miksza DR, Zaia CTBV, Zaia DAM, de Souza HM, Bertolini GL.
    Cell Biochem Funct; 2021 Aug 01; 39(6):754-762. PubMed ID: 33913177
    [Abstract] [Full Text] [Related]

  • 48. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
    Miehle K, Stumvoll M, Fasshauer M, Hierl T.
    Endocrine; 2017 Nov 01; 58(2):262-266. PubMed ID: 28993984
    [Abstract] [Full Text] [Related]

  • 49. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ.
    Clin Endocrinol (Oxf); 2016 Jul 01; 85(1):137-49. PubMed ID: 26589105
    [Abstract] [Full Text] [Related]

  • 50. Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy.
    Cook K, Adamski K, Gomes A, Tuttle E, Kalden H, Cochran E, Brown RJ.
    J Endocr Soc; 2021 Apr 01; 5(4):bvab019. PubMed ID: 33817539
    [Abstract] [Full Text] [Related]

  • 51. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
    Lambadiari V, Kountouri A, Maratou E, Liatis S, Dimitriadis GD, Karpe F.
    Front Endocrinol (Lausanne); 2021 Apr 01; 12():684182. PubMed ID: 34168618
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.
    Wu H, Sui C, Xu H, Xia F, Zhai H, Zhang H, Weng P, Han B, Du S, Lu Y.
    J Diabetes Res; 2014 Apr 01; 2014():524517. PubMed ID: 25580440
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report.
    Nagayama A, Ashida K, Moritaka K, Hidaka M, Gobaru M, Tanaka S, Hasuzawa N, Akasu S, Goto Y, Motomura S, Hara K, Tsuruta M, Wada N, Nakayama H, Tajiri Y, Nomura M.
    J Endocr Soc; 2019 Nov 01; 3(11):2179-2183. PubMed ID: 31720553
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans.
    Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny P, Waldhäusl W, Shulman GI.
    Diabetes; 2000 May 01; 49(5):701-7. PubMed ID: 10905476
    [Abstract] [Full Text] [Related]

  • 58. Jejunal gluconeogenesis associated with insulin resistance level and its evolution after Roux-en-Y gastric bypass.
    Gutierrez-Repiso C, Garcia-Serrano S, Moreno-Ruiz FJ, Alcain-Martinez G, Rodriguez-Pacheco F, Garcia-Fuentes E.
    Surg Obes Relat Dis; 2017 Apr 01; 13(4):623-630. PubMed ID: 28089435
    [Abstract] [Full Text] [Related]

  • 59. Regulation of gluconeogenesis during rest and exercise in the depancreatized dog.
    Wasserman DH, Johnson JL, Bupp JL, Lacy DB, Bracy DP.
    Am J Physiol; 1993 Jul 01; 265(1 Pt 1):E51-60. PubMed ID: 8338154
    [Abstract] [Full Text] [Related]

  • 60. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients.
    Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quiñones-Galvan A, Sironi AM, Natali A, Ferrannini E.
    Diabetes; 2001 Aug 01; 50(8):1807-12. PubMed ID: 11473042
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.